Evidence map›Paper›PMID 33437969›Full record

ArticleSTAR protocols2021

Protocol to select conformation-specific intracellular antibodies for targeted protein degradation in an engineered cell line.

Nicolas Bery, Gilles Favre, Aurélien Olichon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nicolas BeryCentre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037 INSERM - Université Toulouse III - ERL5294 CNRS, Toulouse, 31100, France.
Gilles FavreCentre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037 INSERM - Université Toulouse III - ERL5294 CNRS, Toulouse, 31100, France.
Aurélien OlichonCentre de Recherche en Cancérologie de Toulouse (CRCT), UMR1037 INSERM - Université Toulouse III - ERL5294 CNRS, Toulouse, 31100, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we provide a protocol for the selection of conformation-specific intracellular antibody degraders using a cell-based screening method. We applied this protocol to select antibody-based degraders targeting the active form of the small GTPase RHOB (i.e., RHOB-GTP) using an engineered H2882 cell line. The protocol can be used to study the function of RHOB active conformation in various cellular settings. This protocol can be broadly applied to select any kind of intracellular antibody degraders, regardless of conformational state. For complete details on the use and execution of this protocol, please refer to Bery et al. (2019).

Indexed as

Cell EngineeringProteolysisCell LineHumansProtein ConformationrhoB GTP-Binding ProteinSingle-Chain AntibodiesrhoB GTP-Binding ProteinRHOB protein, humanSingle-Chain AntibodiesAntibodyCell-based assaysCell biologyMolecular/chemical probesProtein biochemistry

Identifiers

PMID33437969
PMCPMC7786126
OpenAlexW3115367109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.